EGFR and non-small cell lung carcinoma: First-generation EGFR-TKIs, in combination with anti-angiogenesis agents, including bevacizumab and ramucirumab, for the treatment of advanced EGFR-mutated NSCLC, have been investigated in several studies [15,16,17,19].